Literature DB >> 3343850

Improved results of surgical treatment for esophageal and gastroesophageal junction carcinomas after preoperative combined chemotherapy and radiation.

S D MacFarlane1, L D Hill, P C Jolly, R A Kozarek, R P Anderson.   

Abstract

Combined treatment with chemotherapy and radiation (chemoradiation) preceding surgical exploration for esophageal or gastroesophageal squamous cell carcinoma or adenocarcinoma was compared with surgical exploration alone to determine if there was an influence on tumor status at exploration, tumor resectability, disease recurrence, and patient survival. Preoperative chemoradiation resulted in significant tumor response as measured by decreased nodal involvement and 36% incidence of no residual tumor at resection (total response) and was reflected by an improvement in resectability. Local tumor recurrence was eliminated by preoperative chemoradiation preceding resection. Distant recurrence was not reduced and remained the major cause of death. The 2-year survival rate after tumor resection alone was 33% versus 66% after preoperative chemoradiation and resection (p = 0.13). Patient survival after resection alone was predicted by pathologic extent of local disease as measured by lymph node status. In contrast, survival after chemoradiation and resection was not predicted by pathologic extent of local disease. Surgical resection appears to have been an important component of therapy, primarily because survival was improved in patients after resection of residual local disease.

Entities:  

Mesh:

Year:  1988        PMID: 3343850

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

1.  Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.

Authors:  H Sekiguchi; S Akiyama; M Fujiwara; H Nakamura; K Kondo; Y Kasai; K Ito; J Sakamoto; H Takagi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  The results of esophagogastrectomy without thoracotomy for adenocarcinoma of the esophagogastric junction.

Authors:  R J Finley; R I Inculet
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

Review 3.  Multimodal treatment for squamous cell esophageal cancer.

Authors:  U Fink; H J Stein; H Wilke; J D Roder; J R Siewert
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the esophagus.

Authors:  J R Stewart; S J Hoff; D H Johnson; M J Murray; D R Butler; C C Elkins; K W Sharp; W H Merrill; J L Sawyers
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

5.  Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.

Authors:  M K Ferguson; L B Reeder; P C Hoffman; D J Haraf; L C Drinkard; E E Vokes
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

6.  Preoperative high-dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  E R Sauter; L R Coia; S M Keller
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

7.  Limited esophagogastrectomy for carcinoma of the cardia. Indications, technique, and results.

Authors:  F H Ellis; S P Gibb; E Watkins
Journal:  Ann Surg       Date:  1988-09       Impact factor: 12.969

8.  The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.

Authors:  F G Duhaylongsod; M R Gottfried; J D Iglehart; A L Vaughn; W G Wolfe
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

9.  Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction.

Authors:  A D'Errico; C Barozzi; M Fiorentino; R Carella; M Di Simone; L Ferruzzi; S Mattioli; W F Grigioni
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

10.  Impact of Treatment Coordination on Overall Survival in Rectal Cancer.

Authors:  Kevin Biju; George Q Zhang; Miloslawa Stem; Rebecca Sahyoun; Bashar Safar; Chady Atallah; Jonathan E Efron; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2021-01-23       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.